COLUMBUS, Ohio--(BUSINESS WIRE)-- Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that David Dismuke, Ph.D., Chief Technical Officer, will present at the American Society of Gene and Cell Therapy’s (ASGCT) 24^th annual meeting, being held virtually May 10-14, 2021.

The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.

“We are proud to be presenting our exciting data at this prominent global gathering of scientists, researchers and industry leaders committed to transforming genetic medicine and access to gene and cell therapies for patients,” said Timothy J. Miller, Ph.D, CEO, President and Co-Founder of Forge Biologics. “Dr. Dismuke is an authority in gene therapy manufacturing and vector design—his work on pEMBR, our improved adenovirus ad helper plasmid for AAV production, is one example of the unique technology he has developed at Forge to provide better manufacturing solutions for our clients.”

Dr. Dismuke’s presentation, “Development of pEMBR™—An Improved Adenovirus Helper Plasmid for AAV Production,” is scheduled for Friday, May 14, at 12:45 p.m. ET. It is Abstract Number 224, and it will be available on demand during the conference, while the presentation will be viewable for 30 days following the conclusion of the meeting.

“I am honored to be sharing data on pEMBR at such a notable gene therapy conference. pEMBR was designed with the goal of creating an adenovirus helper plasmid that is easier to manufacture and safer, while still providing high productivity of recombinant AAV vectors,” said David Dismuke, Ph.D.

Details for the 2021 ASGCT virtual meeting are available on the meeting website at https://annualmeeting.asgct.org.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 ft² facility in Columbus, Ohio, “The Hearth,” to serve as their headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.

For more information, please visit www.forgebiologics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005427/en/